Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Top Cited Papers
- 20 May 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 20 (7), 924-937
- https://doi.org/10.1016/s1470-2045(19)30167-6
Abstract
No abstract availableKeywords
Funding Information
- F. Hoffmann-La Roche
This publication has 21 references indexed in Scilit:
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialThe Lancet, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature, 2014
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1Clinical Cancer Research, 2012
- A recycling framework for the construction of Bonferroni‐based multiple testsStatistics in Medicine, 2009
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- A Confidence Interval for the Median Survival TimeBiometrics, 1982